Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.

MLA

Li, Xin, et al. “Pharmacological Inhibition of Noncanonical EED-EZH2 Signaling Overcomes Chemoresistance in Prostate Cancer.” Theranostics, vol. 11, no. 14, May 2021, pp. 6873–90. EBSCOhost, https://doi.org/10.7150/thno.49235.

APA

Li, X., Gera, L., Zhang, S., Chen, Y., Lou, L., Wilson, L. M., Xie, Z.-R., Sautto, G., Liu, D., Danaher, A., Mamouni, K., Yang, Y., Du, Y., Fu, H., Kucuk, O., Osunkoya, A. O., Zhou, J., & Wu, D. (2021). Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics, 11(14), 6873–6890. https://doi.org/10.7150/thno.49235

Chicago

Li, Xin, Lajos Gera, Shumin Zhang, Yanhua Chen, Lei Lou, Lauren Marie Wilson, Zhong-Ru Xie, et al. 2021. “Pharmacological Inhibition of Noncanonical EED-EZH2 Signaling Overcomes Chemoresistance in Prostate Cancer.” Theranostics 11 (14): 6873–90. doi:10.7150/thno.49235.